Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Clin Cancer Res. 2011 Apr 11;17(11):3706–3715. doi: 10.1158/1078-0432.CCR-10-3082

Figure 2. AZD7762 sensitizes pancreatic cancer cells to gemcitabine and affects cell cycle checkpoints.

Figure 2

A, Schedule of treatments. B, MiaPaCa-2, M-Panc96, BxPC-3, and Panc-1 cells were treated with gemcitabine (0 – 5 uM) and AZD7762 (100nM) according to the schedule illustrated (A). At the end of the treatment period cells were processed for clonogenic survival. C, MiaPaCa-2 cells were treated with gemcitabine (50 nM) and AZD7762 (100 nM) according to treatment schedule 2. Cells were collected for immunoblotting at t = 26 and 30 hours. The surviving fraction was normalized to the control plating efficiency for `Gem Alone' samples and to the AZD7762 plating efficiency for `Gem + AZD7762' samples for each schedule (B). Data are the mean of n = 3 – 6 independent experiments (B) or are representative of 3 independent experiments (C).